Clinical Trial Update: 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis [Phase 3]

View source ↗

Summary

Phase 3 trial updates show 16-week efficacy and 2-year safety, tolerability, and efficacy data for secukinumab in active psoriatic arthritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Arthritis, Psoriatic | Phase 3 | Status: COMPLETED | Results posted: 2019-07-02